China Resources Pharmaceutical : ANNOUNCEMENT UNAUDITED FINANCIAL RESULTS OF CR SANJIU FOR THE THREE MONTHS ENDED 31 MARCH 2021

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

(Incorporated in Hong Kong with limited liability)

(Stock Code: 3320)

ANNOUNCEMENT

UNAUDITED FINANCIAL RESULTS OF CR SANJIU FOR

THE THREE MONTHS ENDED 31 MARCH 2021

On 29 April 2021, CR Sanjiu released its quarterly report for the three months ended 31 March 2021.

China Resources Sanjiu Medical & Pharmaceutical Company Limited（華潤三九醫藥股 份有限公司）("CR Sanjiu") is a company incorporated in the People's Republic of China. The shares of CR Sanjiu are listed on the Shenzhen Stock Exchange. As of the date of this announcement, CR Sanjiu is indirectly owned as to approximately 63.60% by China Resources Pharmaceutical Group Limited (the "Company", together with its subsidiaries, the "Group") and is a subsidiary of the Company.

On 29 April 2021, CR Sanjiu released its quarterly report for the three months ended 31 March 2021 (the "CR Sanjiu Unaudited Financials"). Set out below are the key financial information of the CR Sanjiu Unaudited Financials:

1

	For the three months ended 31 March
	2021	2020
	(RMB)	(RMB)
	(unaudited)	(unaudited)
Revenue	4,079,841,527.03	3,161,338,689.03
Net profit	647,781,924.14	527,293,843.08
Net decrease in cash and cash equivalents	(1,030,562,498.23)	(1,546,608,396.59)
Cash and cash equivalents at the end of the period	1,948,090,702.18	1,341,126,679.38
	As of	As of
	31 March	31 December
	2021	2020
	(RMB)	(RMB)
	(unaudited)	(audited)
Total assets	22,252,318,769.55	22,010,147,281.16
Total liabilities	7,482,401,425.14	7,951,103,379.26
Owner's equity	14,769,917,344.41	14,059,043,901.90

The CR Sanjiu Unaudited Financials have been prepared in accordance with the PRC Generally Accepted Accounting Principles, have not been reviewed or audited by the Company's auditors, and may require adjustment during the course of auditing. For further details of the CR Sanjiu Unaudited Financials, please refer to the quarterly report for the three months ended 31 March 2021 published by CR Sanjiu on the website of the Shenzhen Stock Exchange (www.szse.cn).

2

The financial information set out in this announcement is limited to CR Sanjiu only and does not represent or provide a complete view of the operational or financial status of the Group.

Shareholders and potential investors should exercise caution when dealing in securities of the Company and should not rely solely on such information.

By order of the Board

China Resources Pharmaceutical Group Limited

Wang Chuncheng

Chairman

Shenzhen, 30 April 2021

As at the date of this announcement, the Board comprises Mr. Wang Chuncheng as chairman and non-executive Director, Mr. Han Yuewei, Mr. Li Xiangming and Mdm. Weng Jingwen as executive Directors, Mr. Yu Zhongliang, Mdm. Guo Wei, Mr. Hou Bo and Mr. Qing Mei Ping Cuo as non-executive Directors and Mdm. Shing Mo Han Yvonne, Mr. Kwok Kin Fun, Mr. Fu Tingmei and Mr. Zhang Kejian as independent non-executive Directors.

3